Difluoromethylornithine rebalances aberrant polyamine ratios in Snyder–Robinson syndrome
EMBO Molecular Medicine · 2023
DOI: 10.15252/emmm.202317833 ↗Kurz gefasst
Fachartikel in der Zeitschrift EMBO Molecular Medicine, 2023. Verfasst von Tracy Murray Stewart und 8 weiteren Autor:innen. Beteiligte Einrichtung: Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA. Hauptthemen laut MEDLINE: Polyamines, Spermidine. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCRR NIH HHS, NICHD NIH HHS, NCI NIH HHS.
Abstract (Originalsprache)
Snyder–Robinson syndrome (SRS) results from mutations in spermine synthase (SMS), which converts the polyamine spermidine into spermine. Affecting primarily males, common manifestations of SRS include intellectual disability, osteoporosis, hypotonia, and seizures. Symptom management is the only treatment. Reduced SMS activity causes spermidine accumulation while spermine levels are reduced. The resulting exaggerated spermidine:spermine ratio is a biochemical hallmark of SRS that tends to correlate with symptom severity. Our studies aim to pharmacologically manipulate polyamine metabolism to correct this imbalance as a therapeutic strategy for SRS. Here we report the repurposing of 2‐difluoromethylornithine (DFMO), an FDA‐approved inhibitor of polyamine biosynthesis, in rebalancing spermidine:spermine ratios in SRS patient cells. Mechanistic in vitro studies demonstrate that, while reducing spermidine biosynthesis, DFMO also stimulates the conversion of spermidine into spermine in hypomorphic SMS cells and induces uptake of exogenous spermine, altogether reducing the aberrant ratios. In a Drosophila SRS model characterized by reduced lifespan, DFMO improves longevity. As nearly all SRS patient mutations are hypomorphic, these studies form a strong foundation for translational studies with significant therapeutic potential.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, Baltimore, MD, USA.
- Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, Moscow, Russia.
- Department of Molecular and Cellular Pharmacology, University of Miami Miller School of Medicine, Miami, FL, USA.
ORCID-Profile: Tracy Murray Stewart, Cassandra E Holbert, Maxim Khomutov, Xianzun Tao, Alex R Khomutov
Förderung
- NCRR NIH HHS
- NICHD NIH HHS
- NCI NIH HHS
- NINDS NIH HHS
- NCATS NIH HHS
- Chan Zuckerberg Initiative
- Commonwealth Foundation for Cancer Research Foundation
- HHS | National Institutes of Health
Zitieren
APA
Stewart, T. M., Foley, J. R., Holbert, C. E., Khomutov, M., Rastkari, N., Tao, X., Khomutov, A. R., Zhai, R. G., & Casero, R. A. (2023). Difluoromethylornithine rebalances aberrant polyamine ratios in Snyder–Robinson syndrome. EMBO Molecular Medicine. https://doi.org/10.15252/emmm.202317833
Vancouver
Stewart TM, Foley JR, Holbert CE, Khomutov M, Rastkari N, Tao X, et al. Difluoromethylornithine rebalances aberrant polyamine ratios in Snyder–Robinson syndrome. EMBO Molecular Medicine. 2023. doi:10.15252/emmm.202317833
BibTeX
@article{Stewart2023,
author = {Stewart, Tracy Murray and Foley, Jackson R and Holbert, Cassandra E and Khomutov, Maxim and Rastkari, Noushin and Tao, Xianzun and Khomutov, Alex R and Zhai, R Grace and Casero, Robert A},
title = {Difluoromethylornithine rebalances aberrant polyamine ratios in Snyder–Robinson syndrome},
journal = {EMBO Molecular Medicine},
year = {2023},
doi = {10.15252/emmm.202317833}
}
EUVIMED